Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Teclistamab
Synonyms
Therapy Description

Tecvayli (teclistamab) is a bispecific antibody that targets CD3 and BCMA, potentially resulting in increased immune response against BCMA-expressing tumor cells (Blood Dec 2016, 128 (22) 5668). Tecvayli (teclistamab) is FDA approved for use in adult patients with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Teclistamab Tecvayli JNJ-64007957|BCMAxCD3|JNJ 64007957|JNJ64007957 CD3 Antibody 99 TNFRSF17 Antibody 20 Tecvayli (teclistamab) is a bispecific antibody that targets CD3 and BCMA, potentially resulting in increased immune response against BCMA-expressing tumor cells (Blood Dec 2016, 128 (22) 5668). Tecvayli (teclistamab) is FDA approved for use in adult patients with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06425991 Phase I Teclistamab A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-10) Recruiting USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | AUS 1
NCT06171685 Phase II Teclistamab MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM Recruiting USA 0
NCT05572515 Phase III Teclistamab Carfilzomib + Dexamethasone Bortezomib + Dexamethasone + Pomalidomide A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9) Recruiting USA | TUR | SWE | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS 5
NCT05469893 Phase II Teclistamab Dexamethasone + Lenalidomide Immuno-PRISM (PRecision Intervention Smoldering Myeloma) Recruiting USA 0
NCT03145181 Phase I Teclistamab Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody® Antibody, in Participants With Relapsed or Refractory Multiple Myeloma Active, not recruiting USA | SWE | NLD | FRA | ESP 0
NCT05463939 Expanded access Teclistamab Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients Approved for marketing 0
NCT06505369 Phase II Talquetamab-tgvs Teclistamab Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients (TALTEC) Recruiting NOR | EST | DNK 0
NCT04557098 Phase II Teclistamab A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma Active, not recruiting USA | SWE | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL 1


Additional content available in CKB BOOST